The laboratory and the direct oral anticoagulants

被引：84

作者：

Tripodi, Armando ^{[1
,2
]}

机构：

[1] Univ Milan, Dept Clin Sci & Community Hlth, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy

[2] Ist Ric & Cura Carattere Sci Ca Granda Osped Magg, Milan, Italy

来源：

BLOOD | 2013年 / 121卷 / 20期

关键词：

DIRECT THROMBIN INHIBITOR; DABIGATRAN ETEXILATE; CHROMOGENIC ASSAY; PROTHROMBIN TIME; RIVAROXABAN; PLASMA; RECOMMENDATIONS; IMPACT;

D O I：

10.1182/blood-2012-12-453076

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although direct oral anticoagulants do not need laboratory testing for dose adjustment, there are instances when laboratory measurement of the drug anticoagulant effect may be useful. They include before initiation of treatment, before surgical or invasive procedures, on the occasion of hemorrhagic or thrombotic events, and whenever immediate reversal of anticoagulation is needed. Choice of tests should be primarily based on their prompt availability. Accordingly, the dilute-thrombin or the ecarin clotting times are best suited for dabigatran and the prothrombin time or the anti-FXa for rivaroxaban.

引用

页码：4032 / 4035

页数：4

共 30 条

[1]

[Anonymous], ANN 1 RIV SUMM PROD

[2]

[Anonymous], ANN 1 DAB SUMM PROD

[3] Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories [J].

Asmis, L. M. ;

Alberio, L. ;

Angelillo-Scherrer, A. ;

Korte, W. ;

Mendez, A. ;

Reber, G. ;

Seifert, B. ;

Stricker, H. ;

Tsakiris, D. A. ;

Wuillemin, W. A. .

THROMBOSIS RESEARCH, 2012, 129 (04) :492-498

[4] Plasma-Diluted Thrombin Time to Measure Dabigatran Concentrations During Dabigatran Etexilate Therapy [J].

Avecilla, Scott T. ;

Ferrell, Chris ;

Chandler, Wayne L. ;

Reyes, Morayma .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 137 (04) :572-574

[5]

Baglin T., 2013, J. Thromb. Haemost

[6] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor [J].

Becker, Richard C. ;

Yang, Hongqiu ;

Barrett, Yuchen ;

Mohan, Puneet ;

Wang, Jessie ;

Wallentin, Lars ;

Alexander, John H. .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) :183-187

[7] Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature [J].

Douxfils, Jonathan ;

Mullier, Francois ;

Loosen, Claire ;

Chatelain, Christian ;

Chatelain, Bernard ;

Dogne, Jean-Michel .

THROMBOSIS RESEARCH, 2012, 130 (06) :956-966

[8] Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate [J].

Douxfils, Jonathan ;

Mullier, Francois ;

Robert, Severine ;

Chatelain, Christian ;

Chatelain, Bernard ;

Dogne, Jean-Michel .

THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) :985-997

[9] Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

[10] Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement [J].

Freyburger, Genevieve ;

Macouillard, Gerard ;

Labrouche, Sylvie ;

Sztark, Francois .

THROMBOSIS RESEARCH, 2011, 127 (05) :457-465

← 1 2 3 →